While activating mutations of BRAF, RAS genes and RET/PTC gene rearrangements promote PTC, other genetic and epigenetic modifications that contribute to malignant progression of this type of thyroid cancer are insufficiently defined. The gene discussed is RET; the disease is thyroid gland carcinoma.